DARE logo

DARE
Dare Bioscience Inc

25,091
Mkt Cap
$24.67M
Volume
152,200.00
52W High
$9.19
52W Low
$1.76
PE Ratio
-4.15
DARE Fundamentals
Price
$1.83
Prev Close
$1.81
Open
$1.88
50D MA
$2.07
Beta
0.45
Avg. Volume
187,359.30
EPS (Annual)
-$0.477
P/B
-1.30
Rev/Employee
$425.39
Loading...
Loading...
News
all
press releases
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
More News
News Placeholder
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -73.68% and -62.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +3.45% and -53.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Zacks·5mo ago
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago

Latest DARE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.